Whole body physiologically-based pharmacokinetic models: their use in clinical drug development

Bibliography

• US Food &Drug Administration: Critical Path Initiative Fact Sheet. 2007 US Department of Health and Human Services, USA. Available from: http://www.fda.gov/oc/initiatives/criticalpath/factsheet.html. Accessed Feb 1, 2007
   Google Scholar
• Derendorf H, Lesko LJ, Chaikin P, et al. Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 2000;40(12 Pt 2):1399
   PubMed Web of Science ®Google Scholar
• Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther 2007;82(1):21
   PubMed Web of Science ®Google Scholar
• Barrett JS, Fossler MJ, Cadieu KD, et al. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clin Pharmacol 2008;48(5):632
   PubMed Web of Science ®Google Scholar
• Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 2005;7(3):E503
   PubMed Web of Science ®Google Scholar
• Germani M, Crivori P, Rocchetti M, et al. Evaluation of a physiologically-based pharmacokinetic approach for simulating the first-time-in-animal study. Basic Clin Pharmacol Toxicol 2005;96(3):254
   PubMed Web of Science ®Google Scholar
• Germani M, Crivori P, Rocchetti M, et al. Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. Eur J Pharm Sci 2007;31(3-4):190
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Wada DR, Berling BM, et al. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. J Pharm Sci 2001;90(9):1226
   PubMed Web of Science ®Google Scholar
• Andersen ME, Krishnan K. Physiologically based pharmacokinetics and cancer risk assessment. Environ Health Perspect 1994;102(Suppl):1103
   Google Scholar
• Nestorov I. Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 2007;3(2):235
   PubMed Web of Science ®Google Scholar
• Von Kleist M, Huisinga W. Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution. J Pharmacokinet Pharmacodyn 2007;34(6):789
   PubMed Web of Science ®Google Scholar
• Kawai R, Lemaire M, Steimer JL, et al. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm 1994;22(5):327
   PubMedGoogle Scholar
• Evans MV, Dowd SM, Kenyon EM, et al. A physiologically based pharmacokinetic model for intravenous and ingested dimethylarsinic acid (DMAV) in mice. Toxicol Sci 2008;104(2):250
   PubMed Web of Science ®Google Scholar
• Poulin P, Theil FP. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 2000;89(1):16
   PubMed Web of Science ®Google Scholar
• Poulin P, Schoenlein K, Theil FP. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 2001;90(4):436
   PubMed Web of Science ®Google Scholar
• Willmann S, Lippert J, Schmitt W. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol 2005;1(1):159
   PubMedGoogle Scholar
• Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006;956:1238
   Google Scholar
• Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005;94(6):1259
   PubMed Web of Science ®Google Scholar
• Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro 2008;22(2):457
   PubMed Web of Science ®Google Scholar
• Bjorkman S. Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models. J Pharmacokinet Pharmacodyn 2003;30(4):285
   PubMed Web of Science ®Google Scholar
• Chiu WA, Barton HA, Dewoskin RS, et al. Evaluation of physiologically based pharmacokinetic models for use in risk assessment. J Appl Toxicol 2007;27(3):218
   PubMed Web of Science ®Google Scholar
• Willmann S, Schmitt W, Keldenich J, et al. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 2004;47(16):4022
   PubMed Web of Science ®Google Scholar
• Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001;50(Suppl 1):S41
   PubMed Web of Science ®Google Scholar
• Lave T, Parrott N, Grimm HP, et al. Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 2007;37(10-11):1295
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982;10(2):201
   PubMedGoogle Scholar
• Shim HJ, Kim YC, Lee JH, et al. Interspecies pharmacokinetic scaling of DA-8159, a new erectogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm Drug Dispos 2005;26(7):269
   PubMed Web of Science ®Google Scholar
• Mahmood I. Allometric issues in drug development. J Pharm Sci 1999;88(11):1101
   PubMed Web of Science ®Google Scholar
• Luttringer O, Theil FP, Poulin P, et al. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci 2003;92(10):1990
   PubMed Web of Science ®Google Scholar
• Jones HM, Parrott N, Jorga K, et al. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006;45(5):511
   PubMed Web of Science ®Google Scholar
• Bruckner JV, Keys DA, Fisher JW. The Acute Exposure Guideline Level (AEGL) program: applications of physiologically based pharmacokinetic modeling. J Toxicol Environ Health A 2004;67(8-10):621
   PubMed Web of Science ®Google Scholar
• Kirman CR, Sweeney LM, Meek ME, et al. Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling. Regul Toxicol Pharmacol 2003;38(3):345
   PubMed Web of Science ®Google Scholar
• Young JF, Wosilait WD, Luecke RH. Analysis of methylmercury disposition in humans utilizing a PBPK model and animal pharmacokinetic data. J Toxicol Environ Health A 2001;63(1):19
   PubMed Web of Science ®Google Scholar
• Bonate PL, Howard D. Prospective allometric scaling: does the emperor have clothes? J Clin Pharmacol 2000;40(6):665
   PubMedGoogle Scholar
• Edginton AN, Willmann S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet 2008: In press
   PubMedGoogle Scholar
• International Commission on Radiological Protection (ICRP). Basic anatomical and physiological data for use in radiological protection: reference values. ICRP Publication 89. Amsterdam: Elsevier Science; 2002
   Google Scholar
• Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 2006;45(10):1013
   PubMed Web of Science ®Google Scholar
• Yang F, Tong X, Mccarver DG, et al. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn 2006;33(4):485
   PubMed Web of Science ®Google Scholar
• Edginton AN, Schmitt W, Willmann S. Application of physiology-based pharmacokinetic and pharmacodynamic modeling to individualized target-controlled propofol infusions. Adv Ther 2006;23(1):143
   PubMed Web of Science ®Google Scholar
• Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 2005;59(6):691
   PubMed Web of Science ®Google Scholar
• Ginsberg G, Hattis D, Russ A, et al. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. J Toxicol Environ Health A 2004;67(4):297
   PubMed Web of Science ®Google Scholar
• Price K, Haddad S, Krishnan K. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J Toxicol Environ Health A 2003;66(5):417
   PubMed Web of Science ®Google Scholar
• Dewoskin RS, Thompson CM. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. Regul Toxicol Pharmacol 2008;51(1):66
   PubMed Web of Science ®Google Scholar
• Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol 2003;51(5):395
   PubMed Web of Science ®Google Scholar
• Ginsberg G, Hattis D, Sonawane B. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Toxicol Appl Pharmacol 2004;198(2):164
   PubMed Web of Science ®Google Scholar
• Brown EA, Shelley ML, Fisher JW. A pharmacokinetic study of occupational and environmental benzene exposure with regard to gender. Risk Anal 1998;18(2):205
   PubMed Web of Science ®Google Scholar
• Clewell HJ, Gentry PR, Covington TR, et al. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol Sci 2004;79(2):381
   PubMed Web of Science ®Google Scholar
• Levitt DG, Schnider TW. Human physiologically based pharmacokinetic model for propofol. BMC Anesthesiol 2005;5(1):4
   PubMedGoogle Scholar
• Clewell HJ III, Andersen ME. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 1996;111(1-3):315
   PubMed Web of Science ®Google Scholar
• Willmann S, Hohn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 2007;34(3):401
   PubMed Web of Science ®Google Scholar
• Yokley K, Tran HT, Pekari K, et al. Physiologically-based pharmacokinetic modeling of benzene in humans: a Bayesian approach. Risk Anal 2006;26(4):925
   PubMed Web of Science ®Google Scholar
• Price PS, Conolly RB, Chaisson CF, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003;33(5):469
   PubMed Web of Science ®Google Scholar
• Krishnan K, Johanson G. Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2005;23(1):31
   PubMed Web of Science ®Google Scholar
• Peng B, Andrews J, Nestorov I, et al. Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. Antisense Nucleic Acid Drug Dev 2001;11(1):15
   PubMedGoogle Scholar
• Baxter LT, Zhu H, Mackensen DG, et al. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 1995;55(20):4611
   PubMed Web of Science ®Google Scholar
• Baxter LT, Zhu H, Mackensen DG, et al. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 1994;54(6):1517
   PubMed Web of Science ®Google Scholar
• Ferl GZ, Kenanova V, Wu AM, et al. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther 2006;5(6):1550
   PubMed Web of Science ®Google Scholar
• Ferl GZ, Wu AM, Distefano JJ III. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 2005;33(11):1640
   PubMed Web of Science ®Google Scholar
• Davda JP, Jain M, Batra SK, et al. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 2008;8(3):401
   PubMed Web of Science ®Google Scholar
• Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 2007;34(5):687
   PubMed Web of Science ®Google Scholar
• Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006;72(1):1
   PubMed Web of Science ®Google Scholar
• Ng CM, Stefanich E, Anand BS, et al. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 2006;23(1):95
   PubMed Web of Science ®Google Scholar
• Peters SA. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet 2008;47(4):261
   PubMed Web of Science ®Google Scholar
• Peters SA, Hultin L. Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat. J Pharmacokinet Pharmacodyn 2008;35(1):1
   PubMed Web of Science ®Google Scholar
• Peters SA. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles. Clin Pharmacokinet 2008;47(4):245
   PubMed Web of Science ®Google Scholar
• Theil FP, Guentert TW, Haddad S, et al. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 2003;138(1-2):29
   PubMed Web of Science ®Google Scholar
• Lupfert C, Reichel A. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery. Chem Biodivers 2005;2(11):1462
   PubMed Web of Science ®Google Scholar
• Claudino WM, Quattrone A, Biganzoli L, et al. Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol 2007;25(19):2840
   PubMed Web of Science ®Google Scholar
• De Buck SS, Sinha VK, Fenu LA, et al. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007;35(10):1766
   PubMed Web of Science ®Google Scholar
• Barton HA, Chiu WA, Woodrow SR, et al. Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. Toxicol Sci 2007;99(2):395
   PubMed Web of Science ®Google Scholar
• Loizou G, Spendiff M, Barton HA, et al. Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. Regul Toxicol Pharmacol 2008;50(3):400
   PubMed Web of Science ®Google Scholar